CompletedInterventionalNot ApplicableLast updated Aug 11, 2026

Microneedling-Assisted Delivery of Cetirizine Versus Latanoprost in Alopecia Areata

Microneedling-Assisted Delivery of Cetirizine Versus Latanoprost in Alopecia Areata: A Pilot Randomized Controlled Study

Overview

ClinicalTrials.gov ID: NCT07757867
Lead Sponsor: Tanta UniversityOTHER
Brief Summary: This study planned to measure the effectiveness and safety of microneedling aided administration of cetirizine 1% versus latanoprost 0.01% in alopecia areata.
Study Type: Interventional

Status

Overall Status: Completed
Start Date: Oct 1, 2022Actual
Primary Completion Date: Oct 1, 2024Actual
Completion Date: Oct 1, 2024Actual

Study Record Dates

First Submitted: Aug 6, 2026
First Submitted that Met QC Criteria: Aug 6, 2026
First Posted: Aug 11, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 6, 2026
Last Update Posted: Aug 11, 2026Actual
Last Verified: Aug 2026

NCT05803070Unknown status

Topical Cetirizine in Treatment of Localized Alopecia Areata

NCT06239324Unknown status

Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser

NCT04481412Completed

Topical Cetirizine in Androgenetic Alopecia in Females

NCT02350023Completed

Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata

NCT03535233Completed

Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata

NCT04147845Completed

Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Dioxide Laser or Microneedling in Treatment of Alopecia Areata